IM01.01 4-Year Survival in Randomised Phase II (POPLAR) and Phase III (OAK) Studies of Atezolizumab vs. Docetaxel in 2L+ NSCLC

阿替唑单抗 多西紫杉醇 医学 内科学 不利影响 肿瘤科 组织学 临床研究阶段 总体生存率 免疫疗法 化疗 癌症 彭布罗利珠单抗
作者
Julien Mazières,Achim Rittmeyer,Shirish M. Gadgeel,Toyoaki Hida,David R. Gandara,Diego Cortinovis,Fabrice Barlési,Wei Yu,Christopher Matheny,M. Ballinger,K. Park
出处
期刊:Journal of Thoracic Oncology [Elsevier BV]
卷期号:16 (1): S15-S15
标识
DOI:10.1016/j.jtho.2020.10.048
摘要

Atezolizumab (anti–PD-L1) showed overall survival (OS) benefit over docetaxel in the Phase II (POPLAR; N=287) and Phase III (OAK; N=1225) studies in patients with advanced NSCLC. 4-year survival analysis from both studies is reported. In both studies, patients were randomised 1:1 to receive atezolizumab (1200 mg) or docetaxel (75 mg/m2) intravenously every 3 weeks; PD-L1 expression was assessed by the Ventana SP142 assay on tumour cells (TC) and tumourinfiltrating immune cells (IC); landmark OS was estimated using the Kaplan-Meier method. The minimum follow-up was 53 (POPLAR) and 45 (OAK) months, representing an additional 17 and 19 months of follow-up, respectively, from prior reports. 4-year survival rates with atezolizumab vs docetaxel were 14.8% vs 8.1% and 15.5% vs 8.7% in POPLAR and OAK, respectively. The long-term OS benefit of atezolizumab vs docetaxel was seen across histology and PD-L1 expression subgroups. Of patients in the atezolizumab arms who lived ≥4 years in POPLAR (N=15) and OAK (N=43), 40% and 23% were in the PD-L1–high (TC3 or IC3) subgroup, 33% and 37% were in the PD-L1–negative (TC0 and IC0) subgroup, and 87% and 88% had non-squamous histology, respectively. Among 4-year survivors in the docetaxel arms, 2/4 (50%) and 17/26 (65%) received subsequent immunotherapy in POPLAR and OAK, respectively, vs 3/15 (20%) and 10/43 (23%) in the atezolizumab ar Fewer Grade 3-4 treatment-related adverse events and adverse events leading to treatment withdrawal occurred in the atezolizumab vs docetaxel arms in both studies. 4-year OS rates favoured atezolizumab vs docetaxel across histology and PD-L1 expression subgroups in both studies. The PD-L1–high (TC3 or IC3) subgroups continued to derive the greatest OS benefit with atezolizumab vs docetaxel; however, the PD-L1–negative (TC0 and IC0) subgroups also sustained an improved long-term OS benefit with atezolizumab vs docetaxel. Most patients in the docetaxel arms received subsequent immunotherapy. Atezolizumab treatment was well tolerated, and safety was consistent with prior reports. Previously presented at ESMO Congress 2020, FNP: 1907, Julien Mazieres et al. - Reused with permission
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
001026Z完成签到,获得积分10
1秒前
4秒前
EZ完成签到 ,获得积分10
4秒前
831143完成签到 ,获得积分0
4秒前
5秒前
5秒前
快乐的90后fjk完成签到 ,获得积分10
6秒前
6秒前
orixero应助欣欣采纳,获得10
7秒前
大大杰完成签到,获得积分10
7秒前
Tal完成签到,获得积分10
7秒前
dzy1317发布了新的文献求助10
8秒前
8秒前
大大杰发布了新的文献求助10
10秒前
善良又亦完成签到 ,获得积分10
10秒前
zh发布了新的文献求助10
10秒前
Neonoes完成签到,获得积分10
12秒前
Eason小川发布了新的文献求助10
15秒前
kiyo_v完成签到,获得积分10
18秒前
lengyan发布了新的文献求助10
19秒前
俊逸的香萱完成签到,获得积分10
22秒前
zhang完成签到 ,获得积分10
24秒前
黄花完成签到 ,获得积分10
25秒前
zdnn完成签到,获得积分10
27秒前
小梦完成签到,获得积分10
27秒前
lieeey完成签到,获得积分10
29秒前
不敢装睡完成签到,获得积分10
33秒前
lengyan完成签到,获得积分10
33秒前
yangzhang完成签到,获得积分10
33秒前
Euuii完成签到 ,获得积分10
34秒前
May应助dominate采纳,获得10
34秒前
方圆完成签到 ,获得积分10
35秒前
Xu发布了新的文献求助10
35秒前
37秒前
甜菜完成签到,获得积分10
37秒前
佳佳应助大大杰采纳,获得10
40秒前
吕绪特发布了新的文献求助10
40秒前
42秒前
标致幻然完成签到 ,获得积分10
43秒前
饱满的新之完成签到 ,获得积分10
43秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Cognitive Neuroscience: The Biology of the Mind 1000
Technical Brochure TB 814: LPIT applications in HV gas insulated switchgear 1000
Immigrant Incorporation in East Asian Democracies 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
A Preliminary Study on Correlation Between Independent Components of Facial Thermal Images and Subjective Assessment of Chronic Stress 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3965786
求助须知:如何正确求助?哪些是违规求助? 3511071
关于积分的说明 11156136
捐赠科研通 3245633
什么是DOI,文献DOI怎么找? 1793097
邀请新用户注册赠送积分活动 874230
科研通“疑难数据库(出版商)”最低求助积分说明 804268